Stay updated with breaking news from Rose Weldon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...
CAMBRIDGE, Mass., April 24, 2024 -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1...
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of...
CAMBRIDGE, Mass., June 01, 2024 -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in...